Ticlopidine-induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy

American Journal of Hematology

Volumn 63, Issue 3, 2000, Pages 141-144

  Pullarkat, Vinod A ^a   Rho, Hyan ^a   Murata Collins, Joyce L ^b   Liebman, Howard A ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aplastic anemia; Cyclosporine; Immunosuppressive therapy; Ticlopidine

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; TICLOPIDINE;

AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW EXAMINATION; BRAIN INFARCTION; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 3; FOLLOW UP; HUMAN; HYPOPLASIA; IMMUNOSUPPRESSIVE TREATMENT; MACROCYTIC ANEMIA; MALE; MYELODYSPLASIA; PANCYTOPENIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; BONE MARROW; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CYCLOSPORINE; DEXAMETHASONE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0033997174     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200003)63:3<141::AID-AJH6>3.0.CO;2-T     Document Type: Article

References (21)

1. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
2. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82:17-26.
3. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988;39: 802-811.
4. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitsky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084-1089.
5. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321: 501-507.
6. Yeh SP, Hsueh EJ, Wu H, Wang YC. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol. 1998; 76:87-90.
7. McTavish D, Faulds D, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990;40:238-259.
8. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 1991;37:239-242.
9. Murray JC, Kelly MA, Gorelick PB. Ticlopidine. A new antiplatelet agent for the secondary prevention of stroke. Clin Neuropharmacol 1994;17:23-31.
10. Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Hematol 1997;98:211-213.
11. Rodriguez JN, Fernandez-Jurado A, Dieguez JC, Amian A, Prados D. Ticlopidine and severe aplastic anemia. Am J Hematol 1994;47:332.
12. Weiner P, Zidan F, Paz R. Severe aplastic anemia due to ticlopidine. Isr J Med Sci 1995;31:444-445.
13. Mataix R, Ojeda E, Perez MDC, Jimenez S. Ticlopidine and severe aplastic anemia. Br J Hematol 1992;80:125-126.
14. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, et al. Hematological toxicity of ticlopidine. Am J Hematol 1994;47:149-150.
15. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M. Ticlopidine and severe aplastic anemia. Br J Hematol 1992;82:779-780.
16. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methyl prednisolone with or without cyclosporine. N Engl J Med 1991;324:1297-1304.
17. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia. A prospective randomized trial. N Engl J Med 1983;308:113-118.
18. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P. et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993;329:1152-1157.
19. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Hematol 1995;91:490-501.
20. Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, et al. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVII gene in acute myelogenous leukemias with inv (3) (q21q26). Blood 1994; 84:2681-2688.
21. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.